Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | I-BET151 + Panobinostat |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
I-BET151 | GSK1210151A | BRD3 Inhibitor 2 BRD4 Inhibitor 9 | I-BET151 is a small molecule that blocks Brd3/4 binding to chromatin, resulting in transcription inhibition and potentially leading to tumor cell death (PMID: 21964340, PMID: 30906568, PMID: 32603665). | |
Panobinostat | Farydak | LBH589 | HDAC Inhibitor 41 | Farydak (panobinostat) is an HDAC inhibitor, which induces cell-cycle arrest and decreases growth of tumor cells (PMID: 18349321, PMID: 19671764, PMID: 27802904). Farydak (panobinostat) is FDA approved, in combination with Velcade (Bortezomib) and dexamethasone, for multiple myeloma (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
KMT2A - AFF1 | acute lymphoblastic leukemia | predicted - sensitive | I-BET151 + Panobinostat | Preclinical - Cell line xenograft | Actionable | In a preclinical study, acute lymphoblastic leukemia cell line xenograft models harboring a KMT2A-AFF1 fusion treated with a combination therapy of I-BET151 and Farydak (panobinostat) demonstrated reduced cellularity and a prolonged survival of 34 days compared to 28 days for mice receiving either I-BET151 alone or 21 days for those treated with control (PMID: 29748211). | 29748211 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|